Anlysis of Bio - Pharma in East Asia - Trends Report Biopharmaceutical Report III Issue6_April 2015 Featured Story of Korean Pharma: Hanwha confirms abandoning bid for Dow Chemical basic che...
Astellas/Medivation's Xtandi has questionable potential to displace bicalutamide Biopharmaceutical Report II Issue6_April 2015 Astellas (TYO:4503)/Medivation's (NASDAQ:MDVN) Phase II TERRAIN study topline data on Xtand...
Spark's LCA2 gene therapy is likely to have greater benefit for younger patients Biopharmaceutical Report I Issue6_April 2015 Spark Therapeutics' (NASDAQ:ONCE) subretinal gene therapy injection of SPK-RPE65, is likely ...
Biosimilar Reference Products Expected to Grow Biopharmaceutical Report II Issue5_February 2015 • Logistic complications create high demand for the expertise of comparator suppliers ...
Diabetic Neuropathy Patient Stratification, Chances Boosted Biopharmaceutical Report I Issue5_February 2015 • Phase II signals encouraging for positive Phase III translation • Capsaicin as stra...
J&J may suffer over AbbVie,Amgen in renewed biologic USpayer contracts as Celltrion’sbiosimilar loom Biopharmaceutical Report II Issue4_November 2014 • Remsima use may be forced ahead of Remicade, but not Humira or Enbrel • Celltrio...
Array/Novartis’ binimetinib expected to best chemotherapy in Phase III trial despite protocol change Biopharmaceutical Report I Issue4_November 2015 • Enrollment criteria expanded mid-trial to reflect shifting treatment landscape • ...
The Unrealized Potential of Stem Cell Therapy Biopharmaceutical Report III Issue3_September 2014 Over the last decade or so, I have observed a tempering of what was once a large and g...
*Novartis’ LCZ696 for CHFdraws approval optimism aftermeeting difficult Phase IIIendpoints Biopharmaceutical Report II Issue3_September 2014 • Superiority to standard therapy bodes well for approvals • Regulators may require...
*Celgene's Revlimid has experts optimistic about potential in Phase III non-del (5q) MDS trial in tr Biopharmaceutical Report I Issue3_September 2014 • Historical responses meaningful, but approvability based on transfusion changes unc...
*Merck's Phase III tecemotide vaccine trial in NSCLC in Asian patients could show benefit, but .. Biopharmaceutical Report II Issue2_May 2014 • Marginal OS benefit found in Asian patients in previous trial lends optimism • Vaccine ...
AstraZeneca’s pipeline projections a tough sell, Pfizer will struggle to drive combined value Biopharmaceutical Report I Issue2_May 2014 • Valuations unreliable given large timeframe to market • Likely EU/US pricing pressures t...
AstraZeneca's Phase I/II AZD9291 shows promise in EGFR inhibitor refractory patients - oncologists Biopharmaceutical Report III Issue1_March 2014 "Targets T790M mutation to overcome EGFR inhibitor resistance Could be effective in the fi...
Life science industry's record-setting pace of deals unlikely to end anytime soon Biopharmaceutical Report II Issue1_March 2014 • Recent IPOs have started to lose some steam, one banker notes • Tax inversion key the...
Biopharma in 2013: A Rising Tide Biopharmaceutical Report I Issue1_March 2014 Big launches, clinical success in key therapeutic areas like cancer immunotherapy, and renew...
